Cannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1 Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]
Lire la suiteDo medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers? Sharon R. Sznitman, Monica J. Barratt, Tom Decorte, Pekka Hakkarainen, Simon Lenton, Gary Potter, Bernd Werse and Chris Wilkins Drugs and Alcohol Today, 2019, 19, (4), 251-256, Doi : 10.1108/DAT-06-2019-0021 Abstract Purpose – It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the therapeutic index of their cannabis by attempting to produce particular concentrations of CBD and/or THC. The purpose of this paper is to examine whether small-scalemedical cannabis growers differ fromthose growing for recreational reasons in terms of self-assessed concentrations of THC and CBD [...]
Lire la suiteInfection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique Roland Tubiana et Fabienne Caby, 24e Rencontres du RESPADD - GRECC, "Usages Cliniques des Cannabinoïdes" 21 juin 2019 (...) Inflammation/ Activation immune et CB Chez les PVVIH traités efficacement, la consommation de CB a été associée: – À des niveaux moins élevés de marqueurs d’inflammation (L B TNF-α+ )/ activation immune (L TCD4+ et CD8+ HLA-DR+CD38+) – A une décroissance plus rapide du niveau d’ADN proviralVIH Mécanismes sous jacents CB (Cannabis Sativa) : > 60 cannabinoides, > 200 non cannabinoides • Cannabinoides: Composant capables d’activer la proteine G couplée aux récepteurs CB1 ou CB2 • Les 2 plus étudiés: Δ9-THC [...]
Lire la suiteAnti-inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages From Cystic Fibrosis Abdullah A Tarique, Tama Evron, George Zhang, Mark A Tepper, Mohammed M Morshed, Isabella S G Andersen, Nelufa Begum, Peter D Sly, Emmanuelle Fantino Journal of Cystic Fibrosis, 2020, S1569-1993, (20), 30094-1 doi : 10.1016/j.jcf.2020.03.015. Abstract Background : Lenabasum is an oral synthetic cannabinoid receptor type 2 agonist previously shown to reduce the production of key airway pro-inflammatory cytokines known to play a role in cystic fibrosis (CF). In a double-blinded, randomized, placebo-control phase 2 study, lenabasum lowered the rate of pulmonary exacerbation among patients with CF. The present study was undertaken to investigate anti-inflammatory [...]
Lire la suiteActivation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury Jérémie Joffre, Che-Chung Yeh, Erika Wong, Mayuri Thete, Fengyun Xu, Ivana Zlatanova, Elliot Lloyd, Lester Kobzik, Matthieu Legrand, and Judith Hellman The Journal of Immunology, 2020, 204: 1–20. doi : 10.4049/jimmunol.2000213 Cannabis sativa and its principal components, D9-tetrahydrocannabinol (D9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. [...]
Lire la suiteThe Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model Jacob M. Vigil, Marena A. Montera, Nathan S. Pentkowski, Jegason P. Diviant, Joaquin Orozco, Anthony L. Ortiz, Lawrence J. Rael and Karin N. Westlund Life, 2020, 10, 69, 1-12 doi : 10.3390/life10050069 Abstract : Background : Few models exist that can control for placebo and expectancy effects commonly observed in clinical trials measuring ‘Cannabis’ pharmacodynamics. We used the Foramen Rotundum Inflammatory Constriction Trigeminal Infraorbital Nerve injury (FRICT-ION) model to measure the effect of “full-spectrum” whole plant extracted hemp oil on chronic neuropathic pain sensitivity in mice. Methods : Male BALBc mice were [...]
Lire la suiteSARS-CoV2 induced respiratory distress : Can cannabinoids be added to anti-viral therapies to reduce lung inflammation ? Siddappa N. Byrareddy, Mahesh Mohan Brain, Behavior, and Immunity, 2020, 1-2. doi : 10.1016/j.bbi.2020.04.079 Keywords : SARS-CoV2, Rhesus macaque, Cannabinoids, Inflammation, Cytokine, Lung Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome coronoavirus-2 (SARS-CoV2) has emerged as a global pandemic, which was first reported in Wuhan, China. Recent reports have suggested that acute infection is associated with a cytokine superstorm, which contributes to the symptoms of fever, cough, muscle pain and in severe cases bilateral interstitial pneumonia characterized by ground glass opacity and focal chest infiltrates that can [...]
Lire la suiteDeveloping Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry Matthew T. Welling, Lei Liu, Arno Hazekamp, Ashley Dowell, Graham J. King Medical Cannabis & Cannabinoids, 2019, 2, 1–13 Doi : 10.1159/000496868 Abstract The plant genus Cannabis is a prolific producer of unique pharmaceutically relevant metabolites, commonly referred to as cannabinoids. Robust and standardised methods for the quantification of cannabinoids within botanical and drug forms is a critical step forward for an emerging Cannabis- based pharmaceutical industry, which is poised for rapid expansion. Despite a growing body of analytical methods for the quantification of cannabinoids, few have [...]
Lire la suiteCannabinoids in Gynecological Diseases Petra Luschnig, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 14-21 Doi : 10.1159/000499164 Abstract The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endocannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB1 and CB2) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulatesalmost all levels of [...]
Lire la suiteGPR55-Mediated Effects in Colon Cancer Cell Lines Carina Hasenoehrl, David Feuersinger, Melanie Kienzl, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 22–28 Doi : 10.1159/000496356 Abstract The cannabinoid-responsive G protein-coupled receptor GPR55 and its endogenous ligand L-α lyso-phosphatidylinositol (LPI) have been reported to play a role in several cancers. A proliferation-enhancing effect of GPR55 has been described for several cancer cell lines and LPI has been found elevated in cancer patients. The aim of this study was to investigate whether GPR55 signaling had an effect on the proliferation of colon cancer cell lines. Using cell viability assays and Western blotting, we show that stable overexpression [...]
Lire la suite